BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 26550952)

  • 1. Bromo-honaucin A inhibits osteoclastogenic differentiation in RAW 264.7 cells via Akt and ERK signaling pathways.
    Sapkota M; Li L; Choi H; Gerwick WH; Soh Y
    Eur J Pharmacol; 2015 Dec; 769():100-9. PubMed ID: 26550952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of osteoclastogenic differentiation by Ikarisoside A in RAW 264.7 cells via JNK and NF-kappaB signaling pathways.
    Choi HJ; Park YR; Nepal M; Choi BY; Cho NP; Choi SH; Heo SR; Kim HS; Yang MS; Soh Y
    Eur J Pharmacol; 2010 Jun; 636(1-3):28-35. PubMed ID: 20353769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saurolactam inhibits osteoclast differentiation and stimulates apoptosis of mature osteoclasts.
    Kim MH; Ryu SY; Choi JS; Min YK; Kim SH
    J Cell Physiol; 2009 Dec; 221(3):618-28. PubMed ID: 19653230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High extracellular inorganic phosphate concentration inhibits RANK-RANKL signaling in osteoclast-like cells.
    Mozar A; Haren N; Chasseraud M; Louvet L; Mazière C; Wattel A; Mentaverri R; Morlière P; Kamel S; Brazier M; Mazière JC; Massy ZA
    J Cell Physiol; 2008 Apr; 215(1):47-54. PubMed ID: 17894387
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sargachromanol G inhibits osteoclastogenesis by suppressing the activation NF-κB and MAPKs in RANKL-induced RAW 264.7 cells.
    Yoon WJ; Kim KN; Heo SJ; Han SC; Kim J; Ko YJ; Kang HK; Yoo ES
    Biochem Biophys Res Commun; 2013 May; 434(4):892-7. PubMed ID: 23611776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thymol inhibits RANKL-induced osteoclastogenesis in RAW264.7 and BMM cells and LPS-induced bone loss in mice.
    Sapkota M; Li L; Kim SW; Soh Y
    Food Chem Toxicol; 2018 Oct; 120():418-429. PubMed ID: 30048646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The inhibitory effect and the molecular mechanism of glabridin on RANKL-induced osteoclastogenesis in RAW264.7 cells.
    Kim HS; Suh KS; Sul D; Kim BJ; Lee SK; Jung WW
    Int J Mol Med; 2012 Feb; 29(2):169-77. PubMed ID: 22038020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Macrolactin F inhibits RANKL-mediated osteoclastogenesis by suppressing Akt, MAPK and NFATc1 pathways and promotes osteoblastogenesis through a BMP-2/smad/Akt/Runx2 signaling pathway.
    Li L; Sapkota M; Gao M; Choi H; Soh Y
    Eur J Pharmacol; 2017 Nov; 815():202-209. PubMed ID: 28919027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
    Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
    Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leonurine hydrochloride inhibits osteoclastogenesis and prevents osteoporosis associated with estrogen deficiency by inhibiting the NF-κB and PI3K/Akt signaling pathways.
    Yuan FL; Xu RS; Jiang DL; He XL; Su Q; Jin C; Li X
    Bone; 2015 Jun; 75():128-37. PubMed ID: 25708053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcium-containing crystals enhance receptor activator of nuclear factor κB ligand/macrophage colony-stimulating factor-mediated osteoclastogenesis via extracellular-signal-regulated kinase and p38 pathways.
    Chang CC; Tsai YH; Liu Y; Lin SY; Liang YC
    Rheumatology (Oxford); 2015 Oct; 54(10):1913-22. PubMed ID: 25998451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docosahexaenoic acid is more potent inhibitor of osteoclast differentiation in RAW 264.7 cells than eicosapentaenoic acid.
    Rahman MM; Bhattacharya A; Fernandes G
    J Cell Physiol; 2008 Jan; 214(1):201-9. PubMed ID: 17929247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pterostilbene derivative suppresses osteoclastogenesis by regulating RANKL-mediated NFκB and MAPK signaling in RAW264.7 cells.
    Nikhil K; Sharan S; Roy P
    Pharmacol Rep; 2015 Dec; 67(6):1264-72. PubMed ID: 26481551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
    Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
    Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Yukmijihwang-tang inhibits receptor activator for nuclear Factor-κB ligand-induced osteoclast differentiation.
    Shim KS; Ma CJ; Kim DS; Ma JY
    J Med Food; 2011 Nov; 14(11):1439-47. PubMed ID: 21883017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simvastatin inhibits osteoclast differentiation induced by bone morphogenetic protein-2 and RANKL through regulating MAPK, AKT and Src signaling.
    Yamashita M; Otsuka F; Mukai T; Yamanaka R; Otani H; Matsumoto Y; Nakamura E; Takano M; Sada KE; Makino H
    Regul Pept; 2010 Jun; 162(1-3):99-108. PubMed ID: 20346376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Technetium-99 conjugated with methylene diphosphonate inhibits receptor activator of nuclear factor-κB ligand-induced osteoclastogenesis.
    Gong W; Dou H; Liu X; Sun L; Hou Y
    Clin Exp Pharmacol Physiol; 2012 Oct; 39(10):886-93. PubMed ID: 23013134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Siglec-15 regulates osteoclast differentiation by modulating RANKL-induced phosphatidylinositol 3-kinase/Akt and Erk pathways in association with signaling Adaptor DAP12.
    Kameda Y; Takahata M; Komatsu M; Mikuni S; Hatakeyama S; Shimizu T; Angata T; Kinjo M; Minami A; Iwasaki N
    J Bone Miner Res; 2013 Dec; 28(12):2463-75. PubMed ID: 23677868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidized low density lipoprotein decreases Rankl-induced differentiation of osteoclasts by inhibition of Rankl signaling.
    Mazière C; Louvet L; Gomila C; Kamel S; Massy Z; Mazière JC
    J Cell Physiol; 2009 Dec; 221(3):572-8. PubMed ID: 19725047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.